Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California. more
Time Frame | UBX | Sector | S&P500 |
---|---|---|---|
1-Week Return | -5.88% | -2.27% | -0.57% |
1-Month Return | -14.5% | -3.96% | 1.21% |
3-Month Return | -22.22% | -9.7% | 7.57% |
6-Month Return | -25.83% | -3.37% | 11.45% |
1-Year Return | -32.53% | 3.71% | 28.48% |
3-Year Return | -93.49% | 3.8% | 29.52% |
5-Year Return | -98.66% | 39.78% | 90.66% |
10-Year Return | -99.33% | 106.91% | 203.75% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | 4.78M | 236.00K | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":4.93,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 2.66M | 3.45M | 2.88M | 2.18M | 19.70M | [{"date":"2019-12-31","value":13.52,"profit":true},{"date":"2020-12-31","value":17.51,"profit":true},{"date":"2021-12-31","value":14.62,"profit":true},{"date":"2022-12-31","value":11.07,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (2.66M) | (3.45M) | 1.90M | (1.94M) | (19.70M) | [{"date":"2019-12-31","value":-139.86,"profit":false},{"date":"2020-12-31","value":-181.14,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-102.1,"profit":false},{"date":"2023-12-31","value":-1034.61,"profit":false}] |
Gross Margin | - | - | 39.80% | (823.73%) | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-2069.71,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 91.00M | 91.33M | 61.45M | 57.81M | 44.67M | [{"date":"2019-12-31","value":99.64,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":67.28,"profit":true},{"date":"2022-12-31","value":63.29,"profit":true},{"date":"2023-12-31","value":48.91,"profit":true}] |
Operating Income | (89.65M) | (93.93M) | (56.66M) | (57.57M) | (44.67M) | [{"date":"2019-12-31","value":-8965100000,"profit":false},{"date":"2020-12-31","value":-9393000000,"profit":false},{"date":"2021-12-31","value":-5666500000,"profit":false},{"date":"2022-12-31","value":-5757200000,"profit":false},{"date":"2023-12-31","value":-4466700000,"profit":false}] |
Total Non-Operating Income/Expense | 10.76M | (10.00K) | (7.14M) | 10.77M | 4.52M | [{"date":"2019-12-31","value":99.98,"profit":true},{"date":"2020-12-31","value":-0.09,"profit":false},{"date":"2021-12-31","value":-66.3,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":41.98,"profit":true}] |
Pre-Tax Income | (82.18M) | (93.84M) | (60.73M) | (59.93M) | (39.86M) | [{"date":"2019-12-31","value":-8217700000,"profit":false},{"date":"2020-12-31","value":-9384400000,"profit":false},{"date":"2021-12-31","value":-6072500000,"profit":false},{"date":"2022-12-31","value":-5992700000,"profit":false},{"date":"2023-12-31","value":-3986000000,"profit":false}] |
Income Taxes | (7.30M) | (1.98M) | (686.00K) | (2.18M) | 6.20M | [{"date":"2019-12-31","value":-117.77,"profit":false},{"date":"2020-12-31","value":-31.84,"profit":false},{"date":"2021-12-31","value":-11.06,"profit":false},{"date":"2022-12-31","value":-35.15,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (74.87M) | (91.87M) | (60.04M) | (57.75M) | (46.06M) | [{"date":"2019-12-31","value":-7487300000,"profit":false},{"date":"2020-12-31","value":-9186900000,"profit":false},{"date":"2021-12-31","value":-6003900000,"profit":false},{"date":"2022-12-31","value":-5774700000,"profit":false},{"date":"2023-12-31","value":-4606200000,"profit":false}] |
Income From Continuous Operations | (82.18M) | (93.84M) | (60.73M) | (60.13M) | (52.53M) | [{"date":"2019-12-31","value":-8217700000,"profit":false},{"date":"2020-12-31","value":-9384400000,"profit":false},{"date":"2021-12-31","value":-6072500000,"profit":false},{"date":"2022-12-31","value":-6013400000,"profit":false},{"date":"2023-12-31","value":-5253100000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (74.87M) | (91.87M) | (60.04M) | (57.75M) | (39.86M) | [{"date":"2019-12-31","value":-7487300000,"profit":false},{"date":"2020-12-31","value":-9186900000,"profit":false},{"date":"2021-12-31","value":-6003900000,"profit":false},{"date":"2022-12-31","value":-5774700000,"profit":false},{"date":"2023-12-31","value":-3986000000,"profit":false}] |
EPS (Diluted) | (19.00) | (18.10) | (10.90) | (7.06) | (2.55) | [{"date":"2019-12-31","value":-1900,"profit":false},{"date":"2020-12-31","value":-1810,"profit":false},{"date":"2021-12-31","value":-1090,"profit":false},{"date":"2022-12-31","value":-706,"profit":false},{"date":"2023-12-31","value":-255,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
UBX | |
---|---|
Cash Ratio | 3.31 |
Current Ratio | 3.45 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
UBX | |
---|---|
ROA (LTM) | -30.34% |
ROE (LTM) | -86.95% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
UBX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.70 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.30 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
UBX | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 6.54 |
P/B | 1.36 |
Price/FCF | NM |
EV/R | 29.79 |
EV/Ebitda | NM |
Unity Biotechnology Inc (UBX) share price today is $1.12
Yes, Indians can buy shares of Unity Biotechnology Inc (UBX) on Vested. To buy Unity Biotechnology Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in UBX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Unity Biotechnology Inc (UBX) via the Vested app. You can start investing in Unity Biotechnology Inc (UBX) with a minimum investment of $1.
You can invest in shares of Unity Biotechnology Inc (UBX) via Vested in three simple steps:
The 52-week high price of Unity Biotechnology Inc (UBX) is $2.02. The 52-week low price of Unity Biotechnology Inc (UBX) is $1.1.
The price-to-earnings (P/E) ratio of Unity Biotechnology Inc (UBX) is
The price-to-book (P/B) ratio of Unity Biotechnology Inc (UBX) is 1.36
The dividend yield of Unity Biotechnology Inc (UBX) is 0.00%
The market capitalization of Unity Biotechnology Inc (UBX) is $19.21M
The stock symbol (or ticker) of Unity Biotechnology Inc is UBX